Further studies are now required to examine these effects using primary cells from patients with chronic lymphocytic leukemia (CLL) and to determine in animal models whether 4-1BBL/TNFSF9 up-regulation contributes to HDACi-induced anti-tumor effects in vivo. This evidence concerns the gene TNFSF9 and neoplasm.